GSK is a British multinational pharma company; current moves include shifting R&D to Cambridge as it cuts costs and pursuing Nuvalent in a $9–10B deal, signaling a push to accelerate drug development and lung-cancer programs.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.